Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease

[1]  D. Selkoe,et al.  The ups and downs of Aβ , 2006, Nature Medicine.

[2]  J. Hardy,et al.  Amyloid at the blood vessel wall , 2006, Nature Medicine.

[3]  Rebecca A Betensky,et al.  Kinetics of Cerebral Amyloid Angiopathy Progression in a Transgenic Mouse Model of Alzheimer Disease , 2006, The Journal of Neuroscience.

[4]  M. Frosch,et al.  The Cerebral β‐Amyloid Angiopathies: Hereditary and Sporadic , 2006 .

[5]  Brian J Bacskai,et al.  Progression of Cerebral Amyloid Angiopathy in Transgenic Mouse Models of Alzheimer Disease , 2005, Journal of neuropathology and experimental neurology.

[6]  D. Borchelt,et al.  Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: Relationships to β-amyloid deposition and neurotransmitter abnormalities , 2005, Neurobiology of Disease.

[7]  Jian Xu,et al.  Matrix metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhage , 2005, Journal of the Neurological Sciences.

[8]  F. Bloom,et al.  Mouse models of human neurodegenerative disorders: requirements for medication development. , 2005, Archives of neurology.

[9]  W. H. Jordan,et al.  Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid β , 2005, The Journal of Neuroscience.

[10]  R. Weller,et al.  Cerebrovascular disease and the pathophysiology of Alzheimer's disease. Implications for therapy. , 2004, Panminerva medica.

[11]  H. Tanila,et al.  Longitudinal observation on CSF Aβ42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice , 2004, Neurobiology of Disease.

[12]  D. Borchelt,et al.  APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1 , 2004, Neurobiology of Aging.

[13]  R. Weller,et al.  Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer’s disease Pro-CAA position statement , 2004, Neurobiology of Aging.

[14]  Joanna L. Jankowsky,et al.  Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase , 2004 .

[15]  D. German,et al.  Mouse Models of Alzheimer's Disease: Insight into Treatment , 2004, Reviews in the neurosciences.

[16]  J. Kemp,et al.  PS2APP Transgenic Mice, Coexpressing hPS2mut and hAPPswe, Show Age-Related Cognitive Deficits Associated with Discrete Brain Amyloid Deposition and Inflammation , 2003, The Journal of Neuroscience.

[17]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[18]  D. Borchelt,et al.  Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWE , 2003, Neurobiology of Disease.

[19]  Brian J Bacskai,et al.  In Vivo Imaging of Reactive Oxygen Species Specifically Associated with Thioflavine S-Positive Amyloid Plaques by Multiphoton Microscopy , 2003, The Journal of Neuroscience.

[20]  B. Reisberg,et al.  Vascular cognitive impairment , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[21]  K. Jellinger,et al.  Alzheimer disease and cerebrovascular pathology: an update , 2002, Journal of Neural Transmission.

[22]  D. Borchelt,et al.  Accumulation of proteolytic fragments of mutant presenilin 1 and accelerated amyloid deposition are co-regulated in transgenic mice , 2002, Neurobiology of Aging.

[23]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[24]  D. Borchelt,et al.  Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. , 2001, Biomolecular engineering.

[25]  M. Moskowitz,et al.  Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. , 2001, The American journal of pathology.

[26]  M. Staufenbiel,et al.  Spontaneous Hemorrhagic Stroke in a Mouse Model of Cerebral Amyloid Angiopathy , 2001, The Journal of Neuroscience.

[27]  B T Hyman,et al.  Growth Arrest of Individual Senile Plaques in a Model of Alzheimer's Disease Observed by In Vivo Multiphoton Microscopy , 2001, The Journal of Neuroscience.

[28]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[29]  D. Flood,et al.  Presenilin-1 P264L Knock-In Mutation: Differential Effects on Aβ Production, Amyloid Deposition, and Neuronal Vulnerability , 2000, The Journal of Neuroscience.

[30]  K. Duff,et al.  Quantitative histological analysis of amyloid deposition in Alzheimer’s double transgenic mouse brain , 2000, Neuroscience.

[31]  R. Weller,et al.  Cerebral Amyloid Angiopathy: Accumulation of Aβ in Interstitial Fluid Drainage Pathways in Alzheimer's Disease , 2000, Annals of the New York Academy of Sciences.

[32]  H. Vanderstichele,et al.  Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Selkoe,et al.  The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease , 1998 .

[34]  L. Mucke,et al.  Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Hardy,et al.  Increased Aβ42(43) from cell lines expressing presenilin 1 mutations , 1998, Annals of neurology.

[36]  J. Hardy,et al.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.

[37]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[39]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[40]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[41]  B. Sommer,et al.  Expression of APP in transgenic mice: a Comparison of neuron-specific promoters , 1996, Neurobiology of Aging.

[42]  R. Mantegna,et al.  Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[43]  B. Hyman,et al.  The Lack of Accumulation of Senile Plaques or Amyloid Burden in Alzheimer's Disease Suggests a Dynamic Balance Between Amyloid Deposition and Resolution , 1993, Journal of neuropathology and experimental neurology.

[44]  M. Albert,et al.  Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. , 1989, JAMA.